Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13759695 | 1.00 | PNP (0.64) | PNPMTAP | |
| SCHEMBL19671081 | 1.00 | PNP (0.64) | PNPMTAP | |
| SCHEMBL13765294 | 0.87 | PNP (0.59) | PNPMTAP | |
| SCHEMBL15740144 | 0.86 | PNP (0.65) | PNPMTAP | |
| SCHEMBL14627149 | 0.78 | PNP (1.00) | PNP | |
| SCHEMBL14594138 | 0.78 | PNP (1.00) | PNP | |
| SCHEMBL15740137 | 0.78 | PNP (0.64) | PNPMTAP | |
| SCHEMBL19671128 | 0.78 | PNP (0.64) | PNPMTAP | |
| Galidesivir SCHEMBL25424734 | 0.78 | PNP (1.00) | PNPMTAP | |
| SCHEMBL19671054 | 0.78 | PNP (0.56) | PNPMTAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7560434-B2 | AZA nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | BIOCRYST PHARMACEUTICALS, INC. (US) | 2009-07-14 | — | — | US | disclosed |
| US-7560434-B2 | AZA nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | BIOCRYST PHARMACEUTICALS, INC. (US) | 2009-07-14 | — | — | US | disclosed |
| US-20070099942-A1 | AZA nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | BIOCRYST PHARMACEUTICALS, INC. (US) | 2007-05-03 | — | — | US | disclosed |
| US-20070099942-A1 | AZA nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | BIOCRYST PHARMACEUTICALS, INC. (US) | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099942-A1 | AZA nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | NSUN2, NSUN3, POLR2H | PNP 182/4885MTAP 269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.